DFMO: Targeted risk reduction therapy for colorectal neoplasia

Christina M Laukaitis, Eugene W. Gerner

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Strategies to decrease intracellular polyamine levels have been studied for their efficacy in reducing colorectal cancer (CRC) risk. A successful strategy combined agents that decreased polyamine synthesis by inhibiting ornithine decarboxylase with difluoromethylornithine (DFMO), and increased cellular export of polyamines by activating the spermidine/spermine acetyl transferase with non-steroidal anti-inflammatory drugs (NSAIDs). A Phase III trial treating resected adenoma patients with DFMO plus sulindac demonstrated marked reduction of metachronous adenomas, advanced adenomas and multiple adenomas compared to placebo. This combination regimen was well-tolerated, however there was a non-significant excess of cardiovascular events in the treatment arm compared to placebo as well as modest ototoxicity. Targeting this therapy to people at elevated risk of CRC, and employing clinical and genetic predictors, should improve patient benefit and reduce the risk of side effects to improve the acceptability of this strategy.

Original languageEnglish (US)
Pages (from-to)495-506
Number of pages12
JournalBest Practice and Research: Clinical Gastroenterology
Volume25
Issue number4-5
DOIs
StatePublished - Aug 2011

Fingerprint

Eflornithine
Risk Reduction Behavior
Adenoma
Polyamines
Colorectal Neoplasms
Neoplasms
Placebos
Sulindac
Ornithine Decarboxylase
Spermidine
Spermine
Therapeutics
Transferases
Anti-Inflammatory Agents
Pharmaceutical Preparations

Keywords

  • Chemoprevention
  • Colorectal cancer
  • DFMO
  • Polyamines

ASJC Scopus subject areas

  • Gastroenterology

Cite this

DFMO : Targeted risk reduction therapy for colorectal neoplasia. / Laukaitis, Christina M; Gerner, Eugene W.

In: Best Practice and Research: Clinical Gastroenterology, Vol. 25, No. 4-5, 08.2011, p. 495-506.

Research output: Contribution to journalArticle

@article{d7b4d2e8495c4c5d994dae77b755aa51,
title = "DFMO: Targeted risk reduction therapy for colorectal neoplasia",
abstract = "Strategies to decrease intracellular polyamine levels have been studied for their efficacy in reducing colorectal cancer (CRC) risk. A successful strategy combined agents that decreased polyamine synthesis by inhibiting ornithine decarboxylase with difluoromethylornithine (DFMO), and increased cellular export of polyamines by activating the spermidine/spermine acetyl transferase with non-steroidal anti-inflammatory drugs (NSAIDs). A Phase III trial treating resected adenoma patients with DFMO plus sulindac demonstrated marked reduction of metachronous adenomas, advanced adenomas and multiple adenomas compared to placebo. This combination regimen was well-tolerated, however there was a non-significant excess of cardiovascular events in the treatment arm compared to placebo as well as modest ototoxicity. Targeting this therapy to people at elevated risk of CRC, and employing clinical and genetic predictors, should improve patient benefit and reduce the risk of side effects to improve the acceptability of this strategy.",
keywords = "Chemoprevention, Colorectal cancer, DFMO, Polyamines",
author = "Laukaitis, {Christina M} and Gerner, {Eugene W.}",
year = "2011",
month = "8",
doi = "10.1016/j.bpg.2011.09.007",
language = "English (US)",
volume = "25",
pages = "495--506",
journal = "Bailliere's Best Practice and Research in Clinical Gastroenterology",
issn = "1521-6918",
publisher = "Bailliere Tindall Ltd",
number = "4-5",

}

TY - JOUR

T1 - DFMO

T2 - Targeted risk reduction therapy for colorectal neoplasia

AU - Laukaitis, Christina M

AU - Gerner, Eugene W.

PY - 2011/8

Y1 - 2011/8

N2 - Strategies to decrease intracellular polyamine levels have been studied for their efficacy in reducing colorectal cancer (CRC) risk. A successful strategy combined agents that decreased polyamine synthesis by inhibiting ornithine decarboxylase with difluoromethylornithine (DFMO), and increased cellular export of polyamines by activating the spermidine/spermine acetyl transferase with non-steroidal anti-inflammatory drugs (NSAIDs). A Phase III trial treating resected adenoma patients with DFMO plus sulindac demonstrated marked reduction of metachronous adenomas, advanced adenomas and multiple adenomas compared to placebo. This combination regimen was well-tolerated, however there was a non-significant excess of cardiovascular events in the treatment arm compared to placebo as well as modest ototoxicity. Targeting this therapy to people at elevated risk of CRC, and employing clinical and genetic predictors, should improve patient benefit and reduce the risk of side effects to improve the acceptability of this strategy.

AB - Strategies to decrease intracellular polyamine levels have been studied for their efficacy in reducing colorectal cancer (CRC) risk. A successful strategy combined agents that decreased polyamine synthesis by inhibiting ornithine decarboxylase with difluoromethylornithine (DFMO), and increased cellular export of polyamines by activating the spermidine/spermine acetyl transferase with non-steroidal anti-inflammatory drugs (NSAIDs). A Phase III trial treating resected adenoma patients with DFMO plus sulindac demonstrated marked reduction of metachronous adenomas, advanced adenomas and multiple adenomas compared to placebo. This combination regimen was well-tolerated, however there was a non-significant excess of cardiovascular events in the treatment arm compared to placebo as well as modest ototoxicity. Targeting this therapy to people at elevated risk of CRC, and employing clinical and genetic predictors, should improve patient benefit and reduce the risk of side effects to improve the acceptability of this strategy.

KW - Chemoprevention

KW - Colorectal cancer

KW - DFMO

KW - Polyamines

UR - http://www.scopus.com/inward/record.url?scp=82455192451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82455192451&partnerID=8YFLogxK

U2 - 10.1016/j.bpg.2011.09.007

DO - 10.1016/j.bpg.2011.09.007

M3 - Article

C2 - 22122766

AN - SCOPUS:82455192451

VL - 25

SP - 495

EP - 506

JO - Bailliere's Best Practice and Research in Clinical Gastroenterology

JF - Bailliere's Best Practice and Research in Clinical Gastroenterology

SN - 1521-6918

IS - 4-5

ER -